SAB Biotherapeutics to present repeat-dosing clinical data on SAB-142 for new-onset type 1 diabetes at ADA 2026

SAB Biotherapeutics Inc Ordinary Shares

SAB Biotherapeutics Inc Ordinary Shares

SABS

0.00
  • SAB Biotherapeutics set June conference presentations on SAB-142, its lead immunotherapy in development for newly diagnosed Stage 3 type 1 diabetes.
  • Results have not been presented yet; management pointed to new safety and repeat-dosing findings, pharmacology signals, and mechanistic readouts.
  • Data are positioned to support SAB-142’s potential as a redosable, disease-modifying approach, a key differentiation for longer-term treatment use.
  • The company is running the registrational Phase 2b SAFEGUARD study, with a topline readout targeted for 2H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.